TransCode Therapeutics, Inc. (RNAZ) analyst actions
Rating and price-target actions on RNAZ in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the RNAZ overview →
2 measured RNAZ analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| TransCode Therapeutics Initiates Phase 2a Clinical Trial with TTX-MC138 in Patients with ctDNA Positive Colorectal Cancer | Press release | +0.00% | -2.12% | |
| TransCode Therapeutics Announces Phase 1 Clinical Trial Initiation | Press release | +2.21% | +8.27% |
Keep exploring
More RNAZ: earnings → · SEC filings → · RNAZ overview →